EARNEST Partners’s AstraZeneca AZN Stock Holding History

EARNEST Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13	Closed	-$1.69K	–	361
2023 Q3	$1.69K	Hold	13	–	–	﹤0.01%	1013
2023 Q2	$1.79K	Hold	13	–	–	﹤0.01%	1014
2023 Q1	$1.74K	Hold	13	–	–	﹤0.01%	1009
2022 Q4	$1.7K	Hold	13	–	–	﹤0.01%	1019
2022 Q3	$1K	Hold	13	–	–	﹤0.01%	1025
2022 Q2	$2K	Hold	13	–	–	﹤0.01%	964
2022 Q1	$2K	Hold	13	–	–	﹤0.01%	994
2021 Q4	$1K	Sell	13 -92	-88%	-$10.8K	﹤0.01%	1080
2021 Q3	$13K	Buy	+105	New	+$12.2K	﹤0.01%	579

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EARNEST Partners's AZN Position: Q4 2023 in Review

EARNEST Partners sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 13 shares — an estimated $1.69K sold.

EARNEST Partners first reported a position in AZN in Q3 2021 and held it in 9 quarters. The position peaked at $13K in Q3 2021. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

EARNEST Partners reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 13 AstraZeneca shares in Q4 2023, an estimated $1.69K.
EARNEST Partners first reported a position in AstraZeneca in Q3 2021 and held it in 9 quarters.
EARNEST Partners's AstraZeneca position peaked at $13K in Q3 2021.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.